Vabysmo
The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Listed below are the charts and positions for Vabysmo in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Vabysmo.
18
2030 Global forecast Ranking
Recent articles on PMLiVE featuring Vabysmo
60% of people treated with Vabysmo were able to extend treatment to every four months
If approved, Vabysmo would be the first mechanism of action for nAMD and DME in the EU for over ten years
The data showed, after two years, that 60% of patients treated with Vabysmo could be treated every four months, compared with 45% in year one
Data provided by GlobalData
GlobalData provides trusted intelligence on the world’s largest industries including Pharmaceutical and Medical Devices. With over 2,000 in-house experts, our data-driven, technology-powered approach delivers gold-standard insights to help businesses navigate complex markets and predict future trends.
Our integrated platform empowers 4,000 of the world’s largest companies—including over 70% of FTSE 100 and 60% of Fortune 100 firms—to make timely, informed decisions through unique data, expert analysis, and innovative consulting solutions.
To find out more about how our research and insights can help you, please visit https://www.globaldata.com/who-we-are/why-globaldata/
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE’s Top Pharma List – Methodology